Cargo Therapeutics Inc's ROI from its second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Cargo Therapeutics Inc's ROI in the second quarter of 2025?
Cargo Therapeutics Inc recorded a cumulative net loss of $-222 million during 12 months ending in the second quarter of 2025, resulting in a negative return on investment (ROI) of -64.92%.

Within the Healthcare sector 594 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2025 from 3961 to 4020.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Investment Change TTM	2.24 %	85.15 %	265.4 %	5980.54 %	-
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	238	310	389	429	464
Return On Investment (TTM)	-64.92 %	-54.31 %	-39.84 %	-35.75 %	-44.21 %
CRGX's Overall Ranking	# 4020	# 3961	# 4394	# 3813	# 3972
Seq. Investment Change TTM	-14.19 %	-5.31 %	-2.48 %	29.03 %	55.41 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-222	-216	-168	-154	-148

CRGX Company Profile >> Back to CRGX Roi Comparisons >> See Annual CRGX Return On Investment

Return On Investment CRGX's Ranking
Within:	No.
Industry	# 88
Sector	# 595
Overall	# 4020

Return On Investment Statistics
High	Average	Low
-35.75 %	-90.56 %	-343.73 %
(Sep 30 2024)		(Sep 30 2023)

News about Cargo Therapeutics Inc Return on Investment ROI

From Setbacks to Solutions: CARGO Therapeutics Navigates Strategic Challenges with Promising Tri-Specific CAR T-Cell Therapy CRG-023,

January 29, 2025

CARGO Therapeutics Advances with Innovative CRG-023 Amid Strategic Reevaluation: The Future of B-Cell Lymphoma TreatmentIn a notable development within the biotech landscape, CARGO Therapeutics has announced its decision to discontinue the FIRCE-1 Phase 2 study of its investigational therapy, Firi-cel. This strategic pivot comes at a time when the company is facing significant financial challenges, with a year-to-date performance drop of -76.08%. In the third quarter of 2024 alone, CARGO Therapeutics recorded a staggering cumulative net loss of $87 million, resulting in a negative return on investment (ROI) of -20.09%. Despite these hurdles, the company remains committed to advancing its pipeline, particularly its promising tri-specific CAR T-cell therapy, CRG-023, which has recently gained attention in the lead-up to the American Society of Hematology (ASH) 2024 meeting. Discontinuation of FIRCE-1 StudyThe cessation of the FIRCE-1 Phase 2 study signifies a broader reevaluation of CARGO Therapeutics strategic direction as the company seeks to streamline its operations and focus on its most promising programs. Though such a decision can be disheartening for stakeholders, it may be a necessary step to concentrate resources where they are likely to yield the most significant returns. The challenges faced by Firi-cel underscore the hurdles that many biotech entities contend with in developing effective treatments for complex diseases, shedding light on the unpredictable nature of drug development.

Financial Statements
Cargo Therapeutics Inc's II. Quarter Investments	$ 238 Millions	CRGX's Balance sheet
Cargo Therapeutics Inc's II. Quarter Income	$ -50 Millions	Quarterly CRGX's Income Statement
CRGX's Income by Division		See CRGX's Income by Division

CRGX Annual Return On Investment	(Dec 31 2024) 2024	(Dec 31 2023) 2023
Total Investments in Millions	389	432	0	0	0
Y / Y Investment Growth	-9.92 %	-	-	-	-
Net Income in Millions	-168	-98	0	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-43.06 %	-22.73 %	-	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CRGX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CRGX's Competitors
Subscribers only: Roi for Cargo Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for CRGX's Customers

Other Ratios
CRGX's Roa	CRGX's Inventory Turnover Ratio	CRGX's Growth Rates	CRGX's Dividend Statistics
	CRGX's Profitability Ratios	CRGX's Asset Turnover Ratio	CRGX's Dividend Growth
CRGX's Roe	CRGX's Valuation Ratios	CRGX's Financial Strength Ratios	CRGX's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2025, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:42:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.